Knott David M Jr Purchases Shares of 308,133 Atyr PHARMA INC (NASDAQ:ATYR)

Knott David M Jr acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 308,133 shares of the company’s stock, valued at approximately $1,115,000. Atyr PHARMA comprises about 0.4% of Knott David M Jr’s portfolio, making the stock its 28th largest holding. Knott David M Jr owned about 0.37% of Atyr PHARMA at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Victory Capital Management Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter valued at $37,000. D.A. Davidson & CO. acquired a new stake in Atyr PHARMA during the 4th quarter worth about $141,000. JPMorgan Chase & Co. lifted its stake in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in shares of Atyr PHARMA in the fourth quarter worth about $88,000. Finally, Alterna Wealth Management Inc. purchased a new position in shares of Atyr PHARMA in the fourth quarter worth approximately $36,000. 61.72% of the stock is owned by institutional investors.

Atyr PHARMA Price Performance

NASDAQ ATYR opened at $3.02 on Tuesday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $268.35 million, a PE ratio of -3.21 and a beta of 0.98. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.66. The company has a 50 day moving average price of $3.64 and a two-hundred day moving average price of $3.21.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. As a group, equities analysts predict that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Atyr PHARMA currently has an average rating of “Buy” and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.